Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02530970 · ClinicalTrials.gov registry record
A Post Market Study on the Use of Cormatrix® Cangaroo ECM® (Extracellular Matrix) Envelope
A clinical trial, sponsored by Elutia.
- Completed
- Registry status
- 1,025
- Enrollment target
NCT02530970: Completed study, sponsored by Elutia.
NCT02530970 is a clinical trial that has completed, run by Elutia. The registered enrollment target is 1,025 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02530970 has completed, sponsored by Elutia.
- COMPLETED
- Registry status
- 1,025 participants
- Enrollment target
Study Summary
The objective of the SECURE Study is to actively gather additional information on the use of the CorMatrix® CanGaroo ECM® Envelope in a post market observational study.
Primary Outcome
ECM related adverse events were collected at all study visits.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,025 participants |
| Start Date | 2015-10 |
| Est. Completion | 2018-04 |
What the finished NCT02530970 record still lists
NCT02530970 is an observational study that tracks outcomes without assigning an intervention. Its 1,025 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT02530970 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02530970 about?
NCT02530970 is a clinical study titled "A Post Market Study on the Use of Cormatrix® Cangaroo ECM® (Extracellular Matrix) Envelope". The objective of the SECURE Study is to actively gather additional information on the use of the CorMatrix® CanGaroo ECM® Envelope in a post market observational study.
What is the current status of trial NCT02530970?
This trial is currently completed. The enrollment target is 1,025 participants. The study started on 2015-10. Estimated completion is 2018-04.
Who is sponsoring clinical trial NCT02530970?
This trial is sponsored by Elutia, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02200276 · 1,025 participants · NA
Influenza Immunization in Adults Over Age 75
- NCT02296450 · 1,025 participants
Quality of Life (QoL) Assessment in Cancer Patients and Survivors With Dermatologic Conditions Using Dermatologic QoL Instruments
- NCT06888011 · 1,024 participants · NA
iAmHealthy Clinical Practice Guideline (CPG)
- NCT07216703 · 1,023 participants · Phase 3
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia